



Date : 23 - Jul - 12
B:
L:

Declaration of Interests for ENCePP Studies

INTRODUCTION

SECTION 1: PERSONAL DETAILS

This document includes your personal details and your declaration of interests to be made public in line with the provisions of the ENCePP Code of Conduct. All parts must be duly completed. Your declaration will not be accepted if any fields are left empty. You are responsible for the accuracy and completeness of the submitted information.

The form is designed to be filled in electronically and emailed as PDF to the ENCePP Secretariat for publication on the <u>ENCePP E-Register of Studies</u>. In addition, a printed and hand signed copy has to be returned to the ENCePP Secretariat.

First Name:	Corinne		
, was viamie.			
Last Name:	de Vries		
Organisation / Research	University of Bath		
Centre :	Department of Pharmacy and Pharmacology		
	Claverton Down Bath		
	BA2 6NF		
Country			
Country:	United Kingdom		
Contact e-mail Address:	c.de-vries@bath.ac.uk		
Asthma treatm	ent in pregnancy and the frequency of adverse pregnancy outcomes		
<u> </u>			
ENCePP Study Reference Nu	mber: ENCEPP/SDPP/ 2 6 2 8		
Are you the (Primary) Lead Investigator of the above study? No Yes			
Are you an investigator/rese	archer contributing to the above study No 🗸 Yes		

SECTION 2: DECLARATION OF INTERESTS RELATED TO PHARMACEUTICAL INDUSTRY In this section you must declare any interests in the pharmaceutical industry that you currently have or had within the past 3 years. If you have interests to declare please tick 'Yes' to the relevant questions. All questions in this part must be answered. 2.1 Employment Employment in a pharmaceutical company during past 3 years of study application? Pharmaceutical company includes supply or service companies which contribute to research, development, production and maintenance of a medicinal product. Employment relates to salaries currently being directly paid to you by a pharmaceutical company. 2.2 Financial Interest Financial interests in the capital of a pharmaceutical company? Financial interests relate to current holding of shares of a pharmaceutical company with the exclusion of independently managed investment funds/pensions schemes that are not exclusively based on the pharmaceutical sector. 2.3 Patent Yes 🔘 No Patent for a medicinal product? Relates to a patent for a medicinal product currently owned by either you as individual or your organisation/ research centre, and you as individual are the beneficiary. 2.4 Consultancy Yes 🕜 Consultancy for a pharmaceutical company during the past 3 years of study application? Consultancy refers to provision of advice or services to a pharmaceutical company excluding the concerned study and including but not limited to reviewing activities, data monitoring, statistical analysis, end point committees, regardless of contractual arrangements or any form of remuneration such as consulting fees or honoraria. Note that conference/seminar attendance is not considered a consultancy but should be indicated if subject to fee or honorarium. Please specify the pharmaceutical company, types of consultancy and dates when fees/honoraria paid: Period: Current Past 103 From Year: 2010 From Month: Name of Pharmaceutical Company: Servier Type of consultancy: to provide advice on pharmacoepidemiology studies design Please specify the pharmaceutical company, types of consultancy and dates when fees/honoraria paid: Period: Current Past 12 From Month: From Year: 2009 Name of Pharmaceutical Company: Bayer Schering Healthcare Type of consultancy: to provide advice on pharmacoepidemiology studies Please specify the pharmaceutical company, types of consultancy and dates when fees/honoraria paid: Period: Current Past

to provide advice on pharmacoepidemiology studies design

111

Type of consultancy:

Name of Pharmaceutical Company:

From Year: 2011

	article of the series of the	
ticals		
e on pharmacoepidemiology studies design		
No Ø Yes		
tput in a (scientific) advisory board/steering committee ture strategy, direction or development activities of a product-related strategy, regardless of contractual arra	e with the	
No ○ Yes ⊘		
any other than funds contemplated in the company which is currently being received by your researcer, and you receive no personal gain.		
Comments		
asthma medicine utilisation & safety in pregnancy		
Lower Urinary Tract Symptoms - a descriptive study of diagnosis, treatment and patient characteristics in UK general practice		
ASTHMA TREATMENT AND FREQUENCY OF ADVERSE EVENTS IN UK GENERAL PRACTICE		
No ⊘ Yes ○		
ther interests to be made known to the p	તરે લોક્સ ફેરા કહેવા કરે હતી તો હોંગે હતા. ત્યું પણ પ્રાથમ અને પ્રાથમ છે જો ઉપયોગ છે.	
	public.	
present a potential conflict of interest, including matter		
	rs relating	
present a potential conflict of interest, including matter eclare on my honour that I do not have any further inte	rs relating erests or	
present a potential conflict of interest, including matter eclare on my honour that I do not have any further inte duct of the study. act that I acquire additional interests, I shall promptly n	rs relating erests or notify the	
present a potential conflict of interest, including matter eclare on my honour that I do not have any further inteduct of the study. That I acquire additional interests, I shall promptly in a finterests detailing the changes. The accurate to the best of my knowledge and I consent to	rs relating erests or notify the o my	
	No Yes Carmaceutical company during the past 3 years that in a (scientific) advisory board/steering committee the product related strategy, regardless of contractual arrays and your research, and you receive no personal gain. Comments Comments	